DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/t78737/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- ArmaGen Technologies, Inc.
- biOasis Technologies Inc.
- Fate Therapeutics, Inc.
- Green Cross Corporation
- JCR Pharmaceuticals Co., Ltd.
- Sangamo BioSciences, Inc.
- Shire Plc
- Synageva BioPharma Corp.
Drug Profiles
- AGT-182
- FT-1050
- Gene Therapy to Target Iduronate 2-Sulfatase for Hunter Syndrome
- idursulfase
- idursulfase
- JR-032
- MTf-I2S
- MTfp-I2S
- Next Generation biologics for Pompe, Fabry and Hunter
- SHP-631
For more information visit http://www.researchandmarkets.com/research/t78737/mucopolysaccharido
